|Bid||80.24 x 900|
|Ask||80.42 x 1800|
|Day's Range||77.99 - 80.96|
|52 Week Range||31.51 - 84.76|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||43.06|
|Earnings Date||May 10, 2021 - May 14, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.50|
On Thursday, Diodes got an upgrade for its IBD SmartSelect Composite Rating from 87 to 97. Diodes is now out of buy range after clearing the 73.32 buy point in an ascending base. Diodes earns the No. 7 rank among its peers in the Electronics-Semiconductor Manufacturing industry group.
Shares of Gilead Sciences Inc. were down 0.6% in trading on Thursday, the day after the federal government said it will study the company's COVID-19 drug, Veklury, in pregnant women. The drug, which is also referred to as remdesivir, was the first authorized and then approved treatment for patients with COVID-19 who are at least 12 years old. The new study, which is funded by the National Institutes of Health, will evaluate the safety and efficacy of the drug in pregnant women and non-pregnant women of reproductive age. The researchers also plan to study breast milk from women with COVID-19 who have received the treatment. Veklury generated $2.8 billion in revenue for Gilead in 2020, making up one-quarter of the drugmaker's total revenue for the year. Gilead's stock is down 3.2% over the past 12 months, while the broader S&P 500 is up 16.3%.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: